Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Demeclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | USP2 | O75604 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demeclocycline SCHEMBL20716691 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL13085469 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL20952687 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL3252 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL3253 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL2636809 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL29355123 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL29487284 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL6549174 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL41287 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9533943-B2 | Substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-9522872-B2 | Methods for synthesizing substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522872-B2 | Methods for synthesizing substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9481639-B2 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | PARATEK PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20080003208-A1 | Creatine-ligand compounds and methods of use thereof | AVICENA FROUP, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | AVICENA GROUP, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | AVICENA GROUP, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070155708-A1 | e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella | TRUSTEES OF TUFTS COLLEGE (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155708-A1 | e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella | TRUSTEES OF TUFTS COLLEGE (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2006078925-A2 | A TETRACYCLINE METAL COMPLEX IN A SOLID DOSAGE FORM | WARNER CHILCOTT COMPANY, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2002-06-20 | — | — | US | disclosed |
| US-4684728-A | Solubilizing biologically active compounds with reactive hydrogen atoms | BAYER AKTIENGESELLSCHAFT (DE) | 1987-08-04 | — | — | US | disclosed |
| EP-0017772-B1 | METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY | BAYER AG (DE) | 1982-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155708-A1 | e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella | RAB7A, RPS7, SHPRH | MEN1 2339/4885KMT2A 4633/4885TDP1 3513/4885 |
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | IL1R1, TNF, IL1A | MEN1 2311/4885KMT2A 3996/4885TDP1 1636/4885 |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | MEN1 4065/4885KMT2A 634/4885TDP1 999/4885 |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | CCL11, SSB, TNF | MEN1 2687/4885KMT2A 3218/4885TDP1 1126/4885 |
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | TET1, TET3, MYC | MEN1 1281/4885KMT2A 857/4885TDP1 2522/4885 |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | CKMT1A; CKMT1B, HTT, NLN | MEN1 3422/4885KMT2A 478/4885TDP1 469/4885 |
| US-20080003208-A1 | Creatine-ligand compounds and methods of use thereof | CKMT1A; CKMT1B, TARDBP, SLC7A11 | MEN1 4797/4885KMT2A 1522/4885TDP1 556/4885 |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, DHFR | MEN1 2384/4885KMT2A 1153/4885TDP1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.